Physician profile
Charles Arkin
NPI 1295726636
$14,351.03
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,449 · 2020: $2,429 · 2021: $2,696 · 2022: $2,874 · 2023: $2,686 · 2024: $1,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,883 · Education: $18.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,883.17 |
| Education | $18.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,488.22 | 2019-2024 | Rinvoq, Skyrizi |
| Amgen INC. | $2,818.29 | 2019-2024 | Enbrel, Otezla, Tavneos |
| Novartis Pharmaceuticals Corporation | $1,163.05 | 2019-2024 | |
| Glaxosmithkline, LLC. | $1,033.53 | 2019-2024 | Benlysta |
| Janssen Biotech, INC. | $725.32 | 2020-2023 | Simponi Aria, Remicade, Stelara |
| Pfizer INC. | $498.23 | 2019-2023 | |
| Lilly USA, LLC | $420.05 | 2019-2022 | |
| Ucb, INC. | $378.48 | 2019-2023 | Cimzia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $378.23 | 2019-2024 | Ofev, Cyltezo |
| Horizon Therapeutics Plc | $309.36 | 2019-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $302.09 | 2021-2023 | Lupkynis |
| Astrazeneca Pharmaceuticals Lp | $269.28 | 2021-2024 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $235.65 | 2019-2022 | |
| Celgene Corporation | $203.31 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $199.53 | 2021-2024 | Crysvita |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $144.12 | 2023 | Idacio |
| Ani Pharmaceuticals, INC. | $139.33 | 2024 | Purified Cortrophin Gel |
| Genentech USA, INC. | $138.00 | 2019 | |
| Sandoz INC. | $122.02 | 2023-2024 | Hyrimoz |
| Sobi, INC | $93.78 | 2020-2024 | |
| Regeneron Healthcare Solutions, INC. | $60.87 | 2019 | |
| Radius Health, INC. | $37.47 | 2020-2021 | |
| Genzyme Corporation | $36.36 | 2020-2021 | |
| Organon LLC | $34.79 | 2021-2024 | Hadlima |
| Mallinckrodt Enterprises LLC | $33.96 | 2019 | |
| Janssen Scientific Affairs, LLC | $31.85 | 2019 | |
| Mallinckrodt Hospital Products INC. | $24.28 | 2023 | Acthar |
| Pacira Therapeutics, INC. | $18.03 | 2019 | |
| Mylan Institutional INC. | $13.55 | 2023 | Hulio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Arkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.